CD8A and neoplasm: MDSCs that migrate to tumor sites increase STAT1 activity, leading to low levels of reactive oxygen species (ROS) and high levels of iNOS, NO, and arginase-1, which inhibit CD8+ T cell functions in a nonspecific manner [72].